Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?

References

• Gooley, T. A., Chien JW, Pergam SA, et al. Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2010;363:2091–2101.
   PubMed Web of Science ®Google Scholar
• Santos, G. W., Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347–1353.
   PubMed Web of Science ®Google Scholar
• Giralt S. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637.
   PubMed Web of Science ®Google Scholar
• Storb, R., Deeg HJ, Whitehead J,et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–735.
   PubMed Web of Science ®Google Scholar
• Beatty, P. G., Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–771.
   PubMed Web of Science ®Google Scholar
• Reisner, Y., Kirkpatrick, D., Dupont, B, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet Lond Engl. 1981;2:327–331.
   PubMed Web of Science ®Google Scholar
• Aversa, F., Tabilio A, Velardi A, et al. Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA Haplotype. N Engl J Med. 1998;339:1186–1193.
   PubMed Web of Science ®Google Scholar
• Ciceri, F., Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112:3574–3581.
   PubMed Web of Science ®Google Scholar
• Mehta, J., Singhal S, Gee AP, et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant. 2004;33:389–396.
   PubMed Web of Science ®Google Scholar
• Luznik L, Jalla S, Engstrom LW, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–3464.
   PubMed Web of Science ®Google Scholar
• Eto, M., Mayumi, H., Tomita, Y.,et al. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J Immunol Baltim Md 1950. 1991;146:1402–1409.
   Google Scholar
• Kong, Y. Y., Eto, M., Omoto, K.et al. Regulatory T cells in maintenance and reversal of peripheral tolerance in vivo. J Immunol Baltim Md 1950. 1996;157:5284–5289.
   Google Scholar
• Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–3499.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Mayumi H, Eto M, et al. Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance?. J Immunol Baltim Md 1950. 1990;144:463–473.
   Google Scholar
• Brunstein, C. G., Miller, J. S., Cao, Q.et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117:1061–1070.
   PubMed Web of Science ®Google Scholar
• Kanakry, C. G., Ganguly, S., Zahurak, M.,et al. Aldehyde dehydrogenase expression drives human regulatory t cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5:211ra157.
   PubMed Web of Science ®Google Scholar
• Eto M. Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide- induced tolerance to H-2-compatible, Mls-disparate antigens. J Exp Med. 1990;171:97–113.
   PubMed Web of Science ®Google Scholar
• McSweeney, P. A., Niederwieser, D., Shizuru, J. A.,et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400.
   PubMed Web of Science ®Google Scholar
• Luznik, L., O’Donnell, P.V., Symons, H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2008;14:641–650.
   PubMed Web of Science ®Google Scholar
• Brunstein CGEA. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282–288.
   PubMed Web of Science ®Google Scholar
• Castagna, L., Crocchiolo R, Furst S, et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2014;20:724–729.
   PubMed Web of Science ®Google Scholar
• Castagna, L., Bramanti S, Furst S, et al. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant. 2014;49:1475–1480.
   PubMed Web of Science ®Google Scholar
• Raiola, A. M., Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117–122.
   PubMed Web of Science ®Google Scholar
• Bradstock, K., Bilmon I, Kwan J, et al. Influence of stem cell source on outcomes of allogeneic reduced-intensity conditioning therapy transplants using haploidentical related donors. Biol Blood Marrow Transplant. 2015;21:1641–1645.
   PubMed Web of Science ®Google Scholar
• McCurdy, S. R., Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125:3024–3031.
   PubMed Web of Science ®Google Scholar
• Sugita, J., Kawashima N, Fujisaki T, et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant. 2015;21:1646–1652.
   PubMed Web of Science ®Google Scholar
• Kasamon, Y. L., Bolaños-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:3152–3161.
   PubMed Web of Science ®Google Scholar
• Solomon, S. R., Sizemore, C. A., Sanacore, M., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18:1859–1866.
   PubMed Web of Science ®Google Scholar
• Ruggeri A. Use of bone marrow or peripheral blood stem cell grafts in non T cell depleted haploidentical transplants using post-transplant cyclophosphamide, an ALWP-EBMT analysis. ASH; 2016. Abstract congress #1165.
   Google Scholar
• Bashey A. Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical donor transplantation using post-transplant cyclophosphamide. ASH; 2016. Abstract congress #683.
   Google Scholar
• Raiola, A., Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplant. 2014;49:190–194.
   PubMed Web of Science ®Google Scholar
• Cieri, N., Greco, R, Crucitti, L.et al. Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant. 2015;21:1506–1514.
   PubMed Web of Science ®Google Scholar
• Ciurea SOEA. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1835–1844.
   PubMed Web of Science ®Google Scholar
• Burroughs, L. M., O’Donnell, P. V., Sandmaier, B. M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-Haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1279–1287.
   PubMed Web of Science ®Google Scholar
• Bashey, A., Zhang, X., Sizemore, C. A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–1316.
   PubMed Web of Science ®Google Scholar
• Garciaz, S., Castagna L, Bouabdallah R, et al. Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transplant. 2015;50:880–880.
   PubMed Web of Science ®Google Scholar
• El-Cheikh, J., Crocchiolo, R., Furst, S., et al. Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies: cord blood and haploidentical transplant. Cancer. 2015;121:1809–1816.
   PubMed Web of Science ®Google Scholar
• Ciurea, S. O., Zhang, M. J., Bacigalupo, A. A et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–1040.
   PubMed Web of Science ®Google Scholar
• Solomon, S. R., Sizemore, C. A., Zhang, X., et al. Impact of donor type on outcome after allogeneic hematopoietic cell transplantation for acute leukemia. Biol Blood Marrow Transplant. 2016;22:1816–1822.
   PubMed Web of Science ®Google Scholar
• Rashidi, A., DiPersio JF, Westervelt P, et al. Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute Myeloid Leukemia: a retrospective single-center review. Biol Blood Marrow Transplant. 2016;22:1696–1701.
   PubMed Web of Science ®Google Scholar
• Kanate, A. S., Mussetti, A., Kharfan-Dabaja, M. A., et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors. Blood. 2016;127(7):938–947.
   PubMed Web of Science ®Google Scholar
• Ghosh, N., Karmali, R., Rocha, V., et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016;34:3141–3149.
   PubMed Web of Science ®Google Scholar
• Dietrich, S., Finel, H., Martinez, C., et al. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. Leukemia. 2016;30:2086–2089.
   PubMed Web of Science ®Google Scholar
• Chang Y-J, Huang X-J. Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Semin Hematol. 2016;53:82–89.
   PubMed Web of Science ®Google Scholar
• Wang, Y., Chang, Y. J., Xu, L. P., et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124:843–850.
   PubMed Web of Science ®Google Scholar
• Ruggeri, A., Sun, Y., Labopin, M., et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017;102:401–410.
   PubMed Web of Science ®Google Scholar
• Luznik, L., Bolaños-Meade, J, Zahurak, M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115:3224–3230.
   PubMed Web of Science ®Google Scholar
• Kanakry, C. G., O’Donnell PV, Furlong T, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:3497–3505.
   PubMed Web of Science ®Google Scholar
• Kanakry, C. G., Tsai, H. L., Bolaños-Meade, J., et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124:3817–3827.
   PubMed Web of Science ®Google Scholar
• Lindner, S., Berg T, Riemann J, et al. Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia. Ann Hematol. 2016;95:1023–1025.
   PubMed Web of Science ®Google Scholar
• Mehta, R. S., Saliba RM, Chen J, et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016;173:444–455.
   PubMed Web of Science ®Google Scholar
• Alousi, A. M., Brammer JE, Saliba RM, et al. Phase ii trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21:906–912.
   PubMed Web of Science ®Google Scholar
• Anasetti, C., Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–1496.
   PubMed Web of Science ®Google Scholar
• Bradstock, K. F., Bilmon I, Kwan J, et al. Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21:941–944.
   PubMed Web of Science ®Google Scholar
• Holtick, U., Chemnitz JM, Shimabukuro‐Vornhagen A, et al. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016;96:27–35.
   PubMed Web of Science ®Google Scholar
• Moiseev, I. S., Pirogova OV, Alyanski AL, et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant. 2016;22:1037–1042.
   PubMed Web of Science ®Google Scholar
• Mielcarek, M., Furlong T, O’Donnell PV, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127:1502–1508.
   PubMed Web of Science ®Google Scholar
• Greco, R., Lorentino F, Morelli M, et al. Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood. 2016;128:1528–1531.
   PubMed Web of Science ®Google Scholar
• Solomon, S. R., Sanacore M, Zhang X, et al. Calcineurin inhibitor–free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1828–1834.
   PubMed Web of Science ®Google Scholar
• Carnevale-Schianca, F., Caravelli, D, Gallo, S et al. Post–transplant cyclophosphamide and tacrolimus–mycophenolate mofetil combination prevents graft versus host disease in allogeneic peripheral blood hematopoietic cell transplantation from hla–identical donors. Biol. Blood Marrow Transplant. 2016. DOI:10.1016/j.bbmt.2016.12.636.
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade, J., Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120:4285–4291.
   PubMed Web of Science ®Google Scholar
• Dezern AE, Luznik L, Fuchs EJ, et al. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant. 2011;46:1012–1013.
   PubMed Web of Science ®Google Scholar
• Jaiswal SR, Chatterjee S, Mukherjee S, et al. Pre-transplant sirolimus might improve the outcome of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide for patients with severe aplastic anemia. Bone Marrow Transplant. 2015;50:873–875.
   PubMed Web of Science ®Google Scholar
• Clay, J., Kulasekararaj AG, Potter V et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2014;20:1711–1716.
   PubMed Web of Science ®Google Scholar
• Esteves, I., Bonfim C, Pasquini R et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015;50:685–689.
   PubMed Web of Science ®Google Scholar
• Gupta N, Choudhary D, Sharma SK, et al. Haploidentical hematopoietic SCT for acquired severe aplastic anemia using post-transplant high-dose CY. Bone Marrow Transplant. 2015;50:155–156.
   PubMed Web of Science ®Google Scholar
• Yaqub N, Khalid S, Itrat F, et al. Second BMT for thalassemia major using CY post transplant. Bone Marrow Transplant. 2014;49:845–846.
   PubMed Web of Science ®Google Scholar
• Galambrun, C., Pondarré C, Bertrand Y, et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2013;19:62–68.
   PubMed Web of Science ®Google Scholar
• Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6:638–647.
   PubMed Web of Science ®Google Scholar
• Chang, Y.-J., Zhao XY, Huo MRet al. Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol. 2012;32:268–280.
   PubMed Web of Science ®Google Scholar
• Tischer JEA. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol. 2015;94:1677–1688.
   PubMed Web of Science ®Google Scholar
• Rieger, C. T., Rieger, H, Kolb, H.J, et al. Infectious complications after allogeneic stem cell transplantation: incidence in matched-related and matched-unrelated transplant settings. Transpl Infect Dis Off J Transplant Soc. 2009;11:220–226.
   PubMed Web of Science ®Google Scholar
• Crocchiolo, R., Bramanti, S, Vai, A, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis. 2015;17:242–249.
   PubMed Web of Science ®Google Scholar
• Cieri, N., Oliveira, G, Greco, R, et al. Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood. 2015;125:2865–2874.
   PubMed Web of Science ®Google Scholar
• Roberto, A., Castagna, L, Zanon, V, et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood. 2015;125:2855–2864.
   PubMed Web of Science ®Google Scholar
• Ghiso, A., Raiola, A.M, Gualandi, F, et al. DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant. 2015;50:56–61.
   PubMed Web of Science ®Google Scholar
• Zeidan, A. M., Forde, P.M., Symons, H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2014;20:314–318.
   PubMed Web of Science ®Google Scholar
• Levine, J. E., Braun, T, Penza, S.L et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20:405–412.
   PubMed Web of Science ®Google Scholar
• Jaiswal, S. R., Zaman, S, Chakrabarti, A.et al. Improved outcome of refractory/relapsed acute Myeloid Leukemia after post-transplantation cyclophosphamide-based haploidentical transplantation with myeloablative conditioning and early prophylactic granulocyte colony-stimulating factor-mobilized donor lymphocyte infusions. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2016;22:1867–1873.
   PubMed Web of Science ®Google Scholar
• Platzbecker, U., Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26:381–389.
   PubMed Web of Science ®Google Scholar
• Schroeder, T., Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27:1229–1235.
   PubMed Web of Science ®Google Scholar
• Kochenderfer, J. N., Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129–4139.
   PubMed Web of Science ®Google Scholar
• Bashey, A., Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1581–1588.
   PubMed Web of Science ®Google Scholar
• Koestner, W., Hapke M, Herbst J, et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. Blood. 2011;117:1030–1041.
   PubMed Web of Science ®Google Scholar